Association of β1 and β3 adrenergic receptors gene polymorphisms with insulin resistance and high lipid profiles related to type 2 diabetes and metabolic syndrome;Asociación de los polimorfismos génicos de los receptores adrenérgicos β1 y β3 con la resistencia a la insulina y los perfiles elevados de lípidos relacionados con la diabetes tipo 2 y el síndrome metabólico

Nutricion Hospitalaria

Volumn 29, Issue 6, 2014, Pages 1327-1334

  Burguete García, Ana I ^a   Martínez Nava, Gabriela A ^a   Valladares Salgado, Adán ^b   Bermudez V H ^a   Estrada Velasco, Bárbara ^a   Wacher, Niels ^b   Peralta Romero, Jesús ^b   Garcia Mena, Jaime ^c   Parra, Esteban ^d   Cruz, Miguel ^b  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d Departamento de Genética y Biología Molecular Cinvestav IPN Zacatenco ^*

Author keywords

Adrenergic receptors; Metabolic syndrome; Polymorphism; Type 2 diabetes

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR;

ADULT; AGED; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METABOLISM; MEXICO; MIDDLE AGED;

ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MEXICO; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-3;

EID: 84903532297     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2014.29.6.7367     Document Type: Article

References (37)

1. Mancillas-Adame L, Gómez-Pérez F, Rull-Rodrigo J. Diagnóstico y clasificación de la diabetes mellitus, conceptos actuales Revista de Endocrinología y Nutrición 2002; 10: 63-8.
2. Encuesta Nacional de Salud y Nutrición 2006 ENSANUT. pp 17-121 (http://www.insp.mx/ensanut/)
3. Rull JA, Aguilar-Salinas CA, Rojas R, Rios-Torres JM, Gómez-Pérez FJ, Olaiz G. Epidemiology of Type 2 Diabetes in Mexico. Arch Med Res 2005; 36: 188-96.
4. Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Endocrin Metab Clin 2008; 37: 581-601.
5. Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med 1998; 15: 539-53.
6. Zimmet P, Alberti G, Serrano-Ríos M. Una nueva definición mundial del síndrome metabólico propuesta por la Federación Internacional de Diabetes: fundamento y resultados. Rev Esp Cardiol 2005; 58:1371-6.
7. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
8. Alonso AL, Munguía-Miranda C, Ramos-Ponce D, Hernandez-Saavedra D, Kumate J, Cruz M. Waist Perimeter Cutoff Points and Prediction of Metabolic Syndrome Risk. A Study in a Mexican Population. Archives of Medical Research 2008; 39: 346-51.
9. González-Sarmiento E, Pascual-Calleja I, Laclaustra-Gimeno M, Casasnovas Lenguas JA. Síndrome metabólico y diabetes mellitus. Rev Esp Cardiol 2005; (Supl. 5): 30D-37D.
10. Collins S, Surwit R. The 1-Adrenergic Receptors and the Control of Adipose Tissue Metabolism and Thermogenesis. Recent Prog Horm Res 2001; 56: 309-28.
11. Florez JC. The Genetics of Type 2 Diabetes: A Realistic Appraisal. J Clin Endocrinol Metab 2008; 93: 4633-42.
12. Gaulton KJ, Willer CJ, Li Y, Scott LJ, Conneely KN, Jackson AU, Duren WL, Chines PS, Narisu N, Bonnycastle LL, Luo J, Tong M, Sprau AG, Pugh EW, Doheny KF, Valle TT, Abecasis GR, Tuomilehto J, Bergman RN, Collins FS, Boehnke M, Mohlke KL. Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes. Diabetes 2008; 57: 3136-44.
13. Andreassi MG. Metabolic syndrome, diabetes and atherosclerosis: Influence of gene-environment interaction. Mutat Res 2009; 667: 35-43.
14. Perrino C, Rockman HA. Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure. Curr Opin Cardiol 2007; 22: 443-9.
15. Richter W, Day P, Agrawal R, Bruss MD, Granier S, Wang YL, Rasmussen SGF, Horner K, Wang P, Lei T, Patterson AJ, Kobilka B, Conti M. Signaling from B1-and 12-adrenergic receptors is defined by differential interactions with PDE4. EMBO J 2008; 27: 384-93.
16. Lima JJ, Feng H, Duckworth L, Wang J, Sylvester JE, Kissoon N, Garg H 2007 Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations. Metabolism 2007; 56:757-65.
17. Mason D, Moore D, Green S, Liggett S. A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human 1-Adrenergic Receptor. J Biol Chem 1999; 274: 12670-4.
18. Fragoso JM, Rodríguez-Pérez JM, Pérez-Vielma N, Martínez-Rodríguez N, Vargas-Alarcón G. R1 Adrenergic Receptor Polymorphisms Arg389Gly and Ser49Gly in the Amerindian and Mestizo Population of Mexico. Hum Biol 2005; 77: 515-20.
19. Dionne IJ, Garant MJ, Nolan AA, Pollin T I, Lewis DG, Shuldiner AR, Poehlman ET. Association between obesity and a polymorphism in the i1-adrenoceptor gene (Gly389Arg ADRB1) in Caucasian women. Int J Obesity 2002; 26: 633-9.
20. Gjesing AP, Andersen G, Albrechtsen A, Glümer C, Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O. Studies of Associations between the Arg389Gly polymorphism of the b1-adre nergic receptor gene (ADRB1) and hypertension and obesity in 7677 Danish white subjects. Diabetic Med 2007; 24: 392-7.
21. Nonen S, Yamamoto I, Liu J, Maeda M, Motomura T, Igarashi T, Fujio Y, Azuma J. Adrenergic beta1 receptor polymorphism (Ser49Gly) is associated with obesity in type II diabetic patients. Biol Pharm Bull 2008; 31: 295-8.
22. Büettner R, Schäffler A, Arndt H, Rogler G, Nusser J, Zietz B, Enger I, Hügl S, Cuk A, Schölmerich J, Palitzsch KD. The Trp64Arg Polymorphism of the beta 3-Adrenergic Receptor Gene Is Not Associated with Obesity or Type 2 Diabetes Mellitus in a Large Population-Based Caucasian Cohort. J Clin Endocr Metab 1998; 83:2892-2897.
23. Silver K, Mitchell BD, Walston J, Sorkin JD, Stern MP, Roth J, Shuldiner AR 1997 Trp64Arg beta 3-adrenergic receptor and obesity in Mexican Americans. Hum Genet 1997; 101: 306-11.
24. Widén E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995; 333: 348-51.
25. Oeveren van-Dybicz AM, Vonkeman HE, Bon MA, van den Bergh FA, Vermes I. 3-Adrenergic receptor gene polymorphism and type 2 diabetes in a Caucasian population. Diabetes Obes Metab 2001; 3: 47-51.
26. Tamaki S, Nakamura Y, Tabara Y, Okamura T, Kita Y, Kadowaki T, Tsujita Y, Horie M, Miki T, Ueshima H. Relationship between metabolic syndrome and Trp64arg polymorphism of the beta-adrenergic receptor gene in a general sample: the Shigaraki study. Hypertens Res 2006; 29: 891-6.
27. García-Rubi E, Calles-Escandón J. Insulin resistance and type 2 diabetes mellitus: its relationship with the beta 3-adrenergic receptor. Arch Med Res 1999; 30: 459-64.
28. Oizumi T, Daimon M, Saitoh T, Kameda W, Yamaguchi H, Ohnuma H, Igarashi M, Eguchi H, Manaka H, Tominaga M, Kato T. Genotype Arg/Arg, but not Trp/Arg, of the Trp64Arg Polymorphism of the o3-Adrenergic Receptor is Associated with Type 2 Diabetes and Obesity in a Large Japanese Sample. Diabetes Care 2001; 24: 1579-83.
29. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000; 23: S4-S19
30. Dobiásová M. Atherogenic index of plasma [log(triglycerides/ HDL-cholesterol)]: theoretical and practical implications. Clin Chem 2004; 50: 1113-5.
31. Martinez-Marignac VL, Valladares A, Cameron E, Chan A, Perera A, Globus-Goldberg R, Wacher N, Kumate J, McKeigue P, O'Donnell D, Shriver MD, Cruz M, Parra EJ. Admixture in Mexico City: implications for admixture mapping of type 2 diabetes genetic risk factors. Hum Genet 2007; 120: 807-19.
32. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-42.
33. Strosberg AD. Association of 33-adrenoceptor polymorphism with obesity and diabetes: current status. Trends Pharmacol Sci 1997; 18: 449-54.
34. Perfetti R, Hui H, Chamie K, Binder S, Seibert M, McLenithan J, Silver K, Walston JD. Pancreatic S-cells expressing the Arg64 variant of the v3-adrenergic receptor exhibit abnormal insulin secretory activity. J Mol Endocrinol 2001; 27: 133-44.
35. Walston J, Silver K, Hilfiker H, Andersen RE, Seibert M, Beamer B, Roth J, Poehlman E, Shuldiner AR. Insulin Response to Glucose is lower in Individuals homozygous for the Arg64 Variant of the r-3-Adrenergic Receptor. J Clin Endocrinol Metab 2000; 85: 4019-22.
36. Boden G, Laakso M. Lipids and Glucose in Type 2 Diabetes. Dia betes Care 2004; 27: 2253-9.
37. Polymorphism Trp64Arg of beta 3 adrenoreceptor gene: allelic frequencies and influence on insulin resistance in a multicenter study of Castilla-León. Nutr Hosp 2010; 25 (2): 299-303.